CL2024002824A1 - Inhibidores de tyk2 y usos de los mismos - Google Patents

Inhibidores de tyk2 y usos de los mismos

Info

Publication number
CL2024002824A1
CL2024002824A1 CL2024002824A CL2024002824A CL2024002824A1 CL 2024002824 A1 CL2024002824 A1 CL 2024002824A1 CL 2024002824 A CL2024002824 A CL 2024002824A CL 2024002824 A CL2024002824 A CL 2024002824A CL 2024002824 A1 CL2024002824 A1 CL 2024002824A1
Authority
CL
Chile
Prior art keywords
tyk2 inhibitors
tyk2
inhibitors
inhibition
compositions
Prior art date
Application number
CL2024002824A
Other languages
English (en)
Spanish (es)
Inventor
John Collis Alan
Hosagrahara Vinayak
Srivastava Bhaskar
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2024002824A1 publication Critical patent/CL2024002824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024002824A 2022-03-25 2024-09-23 Inhibidores de tyk2 y usos de los mismos CL2024002824A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269943P 2022-03-25 2022-03-25
US202263371033P 2022-08-10 2022-08-10
US202363490664P 2023-03-16 2023-03-16

Publications (1)

Publication Number Publication Date
CL2024002824A1 true CL2024002824A1 (es) 2025-02-14

Family

ID=88102041

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002824A CL2024002824A1 (es) 2022-03-25 2024-09-23 Inhibidores de tyk2 y usos de los mismos

Country Status (10)

Country Link
US (1) US20250213572A1 (enExample)
EP (1) EP4499104A4 (enExample)
JP (1) JP2025510813A (enExample)
KR (1) KR20240165963A (enExample)
AU (1) AU2023237900A1 (enExample)
CA (1) CA3246157A1 (enExample)
CL (1) CL2024002824A1 (enExample)
MX (1) MX2024011693A (enExample)
TW (1) TW202345799A (enExample)
WO (1) WO2023183901A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024263861A2 (en) * 2023-06-23 2024-12-26 Dana-Farber Cancer Institute, Inc. Methods of treating chronic lymphocytic leukemia
EP4780462A1 (en) * 2023-09-21 2026-07-29 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
CN122341608A (zh) * 2023-11-24 2026-07-03 苏州科睿思制药有限公司 Zasocitinib的晶型及其制备方法和用途
WO2026032374A1 (zh) * 2024-08-07 2026-02-12 正大天晴药业集团股份有限公司 含联环的化合物用于治疗银屑病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors

Also Published As

Publication number Publication date
MX2024011693A (es) 2024-11-08
US20250213572A1 (en) 2025-07-03
CA3246157A1 (en) 2023-09-28
EP4499104A1 (en) 2025-02-05
AU2023237900A1 (en) 2024-10-10
JP2025510813A (ja) 2025-04-15
EP4499104A4 (en) 2025-09-03
KR20240165963A (ko) 2024-11-25
TW202345799A (zh) 2023-12-01
WO2023183901A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CL2022000751A1 (es) Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419)
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
UY38602A (es) Compuestos tricíclicos condensados
CL2022001671A1 (es) Inhibidores de sos1
NI202000078A (es) Compuestos heteroaril tetracíclicos
ECSP21050201A (es) Inhibidores de imidazo[1,2-b]piridazina il-17a
CO2026004964A2 (es) Moduladores de kras
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
ECSP24009853A (es) Compuestos tricíclicos como inhibidores de kras
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2021002804A (es) Terapias de combinacion.
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2024011693A (es) Inhibidores de tirosina-proteina cinasa 2 (tyk2) y usos de los mismos
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2024000714A1 (es) Compuestos espirocíclicos
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CL2023003921A1 (es) Inhibidores de transglutaminasas
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
ECSP24007534A (es) Inhibidores de transglutaminasas
CL2024003257A1 (es) Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer